Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00673-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Eva Le Run und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Immunology and Microbiology (LCIM), Immunopathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID),…. Hauptthemen laut MEDLINE: Imipenem, Mycobacterium abscessus, Microbial Sensitivity Tests, beta-Lactamases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
Treatment of Mycobacterium abscessus pulmonary disease requires multiple antibiotics including intravenous β-lactams (e.g., imipenem). M. abscessus produces a β-lactamase (Bla Mab ) that inactivates β-lactam drugs but less efficiently carbapenems. Due to intrinsic and acquired resistance in M. abscessus and poor clinical outcomes, it is critical to understand the development of antibiotic resistance both within the host and in the setting of outbreaks. We compared serial longitudinally collected M. abscessus subsp. massiliense isolates from the index case of a cystic fibrosis center outbreak and four outbreak-related strains. We found strikingly high imipenem resistance in the later patient isolates, including the outbreak strain (MIC > 512 µg/mL). The phenomenon was recapitulated upon exposure of intracellular bacteria to imipenem. Addition of the β-lactamase inhibitor avibactam abrogated the resistant phenotype. Imipenem resistance was caused by an increase in β-lactamase activity and increased bla Mab mRNA level. Concurrent increase in transcription of the preceding ppiA gene indicated upregulation of the entire operon in the resistant strains. Deletion of the porin mspA coincided with the first increase in MIC (from 8 to 32 µg/mL). A frameshift mutation in msp2 responsible for the rough colony morphology and a SNP in ATP-dependent helicase hrpA cooccurred with the second increase in MIC (from 32 to 256 µg/mL). Increased Bla Mab expression and enzymatic activity may have been due to altered regulation of the ppiA-bla Mab operon by the mutated HrpA alone or in combination with other genes described above. This work supports using carbapenem/β-lactamase inhibitor combinations for treating M. abscessus , particularly imipenem-resistant strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Immunology and Microbiology (LCIM), Immunopathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
- Department of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Laboratory Medicine (DLM), Microbiology Service, Clinical Center, NIH, Bethesda, Maryland, USA.
ORCID-Profile: Eva Le Run, Adrian M Zelazny
Förderung
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Le Run, E., Tettelin, H., Holland, S. M., & Zelazny, A. M. (2024). Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00673-24
Vancouver
Le Run E, Tettelin H, Holland SM, Zelazny AM. Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00673-24
BibTeX
@article{LeRun2024,
author = {Le Run, Eva and Tettelin, Hervé and Holland, Steven M and Zelazny, Adrian M},
title = {Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00673-24}
}
EUVIMED